Connect with us

Health

NAFDAC recalls Benylin children syrups

Published

on

By Matthew Denis

The National Agency for Food and Drugs Administration and Control (NAFDAC) has recalled one of Benylin Paediatric Syrups, manufactured by Johnson & Johnson.

NAFDAC disclosed this on its website on Wednesday, stating that the laboratory analysis conducted on the product showed that it contains an unacceptable high level of Diethylene glycol and was found to cause acute oral toxicity in laboratory animals.

“Diethylene glycol is toxic to humans when consumed and can prove fatal. Toxic effects can include abdominal pain, vomiting, diarrhoea, inability to pass urine, headache, altered mental state, and acute kidney injury, which may lead to death,” NAFDAC explained.

Benylin Paediatric syrup is indicated for the relief of cough and its congestive symptoms and for the treatment of hay fever and other allergic conditions in children aged 2 to 12 years.

The details of the product showed that the product was manufactured by Johnson & Johnson in Cape Town, South Africa.

With batch number 329304, the product was manufactured in May 2021, and it is to expire this April 2024.

NAFDAC has, therefore, implored importers, distributors, retailers and consumers to exercise caution and vigilance within the supply chain to avoid the importation, distribution, sale and use of the substandard (contaminated) regulated products.

“All medical products must be obtained from authorised/licensed suppliers. The products’ authenticity and physical condition should be carefully checked.

“Anyone in possession of the above-mentioned product is advised to immediately discontinue sale or use and submit stock to the nearest NAFDAC office. If you witness any adverse reaction/event after the use of this product in any children, you are advised to direct such patients for immediate medical attention from a qualified healthcare professional,” the agency cautioned.

Meanwhile, NAFDAC has urged healthcare professionals and consumers to report any suspicion of substandard and falsified medicines to the nearest NAFDAC office.

Similarly, healthcare professionals and patients are also encouraged to report adverse events or side effects related to the use of the medicinal product to the nearest NAFDAC office, or through the use of the E-reporting platforms available on its website.

Also, the agency has directed the Marketing Authorisation Holder (Johnson and Johnson company West Africa) to initiate the recall of the batch and the notice will also be uploaded to the WHO Global Surveillance and Monitoring System (GSMS).

Health

Assembly passes Kano Pre-Marital Health Screening Bill

Published

on

Kano State House of Assembly has passed a bill for a law to compel intending couples to undergo HIV, hepatitis and sickle cell anaemia screening before marriage.

The passage followed deliberations in the Committee of the Whole House during plenary session,
presided over by the Speaker, Ismail Falgore on Monday in Kano.

After deliberations, the lawmakers approved the 3rd reading of the bill, read by the Deputy Clerk, Alhaji Nasiru Magaji.

Shortly after passage of the bill, the Majority Leader of the house, Lawan Hussein (NNPP-Dala), stated that “any person
intending to marry shall first submit self for medical examinations.”

He said the bill was considered and passed after the 3rd reading, following various legislative processes.

The leader further said that the bill was passed because the state had been battling with different health issues, including
HIV because people go into marriages without medical screening.

He said that the bill, if signed into law, would save many lives and curb the spread of life-threatening diseases.

“The bill will safeguard the health of citizens by institutionalising pre-marital testing to check the spread of diseases
like hepatitis, HIV and sickle cell anaemia,” he added.

Continue Reading

Health

WHO to begin vaccination against Human Papilloma Virus May 27 in Kogi

Published

on

The World Health Organisation (WHO), says it plans to commence vaccination against Human Papilloma Virus (HPV) on May 27 in Kogi.

The state’s Team Lead of WHO, Dr Muktar Toyosi, said this when he led his team on an advocacy visit to the State Council of the Nigeria Union of Journalists (NUJ) on Wednesday in Lokoja.

Toyosi said that the vaccination was meant for girl child of between the age nine and 14.

He said the ongoing sensitisation was to keep the people informed, and educate them on the vaccination of their children to protect them against cervical cancer in future.

”Kogi falls within the second phase of the programme. We are soliciting for the cooperation of the media in educating the people of the state on the HPV vaccination.

“There need for girls child across the state to take the vaccination to safeguard their future.

“Although the vaccine was initially scarce and difficult to get, the good news now is that it has been made available by the government,” Toyosi said.

Also speaking, the State Technical Assistant for WHO, Dr Ahmed Attah, said that the HPV mostly affect women, adding that the vaccination remained a preventive measure against the disease.

Attah, a former state Chairman of the Nigeria Medical Association (NMA) and a former Chief Medical Director (CMD), Kogi Specialist Hospital (KSSH) Lokoja, urged parents and guardians to avail their children of the vaccination to justify government’s investment.

In his response, the Kogi NUJ Chairman, Mr Seidu Ademu, described the health sector as very critical, stressing that the vaccination was a right step in the right direction.

Ademu promised a robust partnership with WHO to enable the team to achieve its set goals.
He stressed the need to inform, educate and sensitise the general public on the need to embrace the vaccine by ensuring that girls within the age range were vaccinated.

Continue Reading

Health

NCDs will be leading cause of mortality in Africa by 2030 – WHO

Published

on

The World Health Organisation (WHO) says Non-communicable Diseases (NCDs) will become the leading cause of mortality in Africa by 2030 if urgent measures are not executed by member states.

Dr Matshidiso Moeti, WHO Regional Director for Africa, joining virtually, made the assertion on Tuesday at the opening of the first International Conference on PEN-Plus in Africa (ICPPA 2024) in Dar es Salaam, Tanzania.

The ICPPA 2024, holding from April 23 to April 25, is aimed at addressing severe NCDs in Africa.

It is being hosted by the WHO Regional Office for Africa, Helmsley Charitable Trust, and the United Republic of Tanzania. Moeti urged member states to embrace strategies that would help to address the issue.

“We are faced with non-communicable diseases and data from low and middle income countries show that 26 per cent of total health spending was due to NCDs, second only to infectious and parasitic diseases.

“Meaning it is urgent to give these often overlooked diseases priority attention as Africa is severely affected and more than in any other place in the world.

“The surge in the burden of NCDs on our continent over the past two decades, is driven by increasing incidences of risk factors, such as unhealthy diets, reduced physical activity, obesity, and air pollution.

“NCDs are set to overtake communicable, maternal, neonatal and nutritional diseases combined as a leading cause of mortality in Africa by 2030.

“And here, the NCDs are called silent epidemics. Unfortunately, this rapid devolution, with a higher mortality rate has not been recognised in the region, because we’re not investing adequately in detecting and lowering the burden of these diseases,” Moeti said.

Moeti noted that severe NCDs like type one diabetes, rheumatic heart disease, and sickle cell disease more frequently affect children and young adults in the majority of Africans population.

She advised that Africa must show increased commitment in addressing NCDs with adequate and sustained resources.

She also said there was the need to strengthen accountability and assess the impact of interventions by enhancing surveillance and monitoring.

According to Moeti, this can be achieved using reliable and timely data at national and sub national levels to drive policy and action as we move forward.

Ms Elke Wisch, UNICEF Representative to Republic of Tanzania, said that collaboration was at the heart of collective response to tackling NCDs.

“Today’s gathering underscores the urgency and importance of addressing NCDs comprehensively and collaboratively.

“The WHO package of essential non communicable  interventions for PEN, for primary healthcare and low resources settings, and the recently launched regional strategy on PEN-Plus provides a strategic framework  for tackling NCDs at their roots,” she said.

Also speaking, Ummy Mwalimu, Minister of Health, Tanzania, said that non communicable diseases NCDs, have become a formidable threat to the health and wellbeing of “our people.”

She urged for collective efforts to address these threats.

“They are silently affecting the lives of our citizens, our communities, undermining the progress we strive to achieve as a nation.

“The impact of these diseases extends beyond individual suffering.

“It affects our communities, our economy, and ultimately the future of our nations in our continent.

“Yet, in the face of these challenges, we are not discouraged together. We have chosen to confront these non-communicable diseases.’’

She urged for lifestyle change as positive way to combatting the negative outcomes of NCDs.

James Reid, Programme Officer for the Helmsley Charitable Trust’s Type 1 Diabetes (T1D) Programme, said he was happy at the level of interest and momentum in engagements to address NCDs, especially Type 2 diabetes.

He, however, identified finance as one of the biggest challenge and hindrance. He said that while political leaders and stakeholders identify the challenges that NCDs pose, the strategies to prevent them, especially NCD care, were limited.

“Leadership for driving of PEN-Plus is very important to make sure that ministry of health leaders and all others involved, really understand how to change the dynamics as well as adopt solutions to suit specific localities,” she said.

WHO’s PEN-Plus (Package of Essential NCD-Plus), is a regional integrated care delivery strategy to address severe non-communicable diseases at first-level referral health facilities.

At the 2022 WHO Regional Committee Meeting for the African Region, the 47 Member States of the AFRO region voted to adopt the PEN-Plus strategy.

It is focused on alleviating the burden among the poorest children and young adults. This is by increasing the accessibility and quality of chronic care services for severe NCDs including Type 1 diabetes, rheumatic heart disease, and sickle cell disease.

 ICPPA 2024 provides opportunity to shore up international support for scaling up PEN-Plus in the African Region. Also, the conference serves as a platform to raise awareness of severe NCDs, share lessons from countries implementing PEN-Plus and identify opportunities to strengthen NCD management.

Continue Reading

Trending